Abstract. Calcium (Ca 2+ ) and magnesium (Mg 2+ ) are important metal elements that regulate a variety of cellular processes such as proliferation, migration, and apoptosis, in cancer cells. Among the ionic channels mediating intracellular entry, the transient receptor potential melastatin type 7 (TRPM7) channel is of particular interest, it being a non-selective, cationic channel mediating both Ca 2+ and Mg 2+ influx. TRPM7 is highly expressed in a number of human cancer tissues and cell lines. In this review, we summarise current knowledge on the physiological role of the dual function TRPM7 chanzyme, the potential application of TRPM7 as a diagnostic and prognostic marker of cancer progression with respect to clinical and pathological characteristics, and the molecular mechanisms implicated in cancerogenesis that specifically involve Ca 2+ and Mg 2+ influx through TRPM7 or kinase activity and interaction with cytoskeletal proteins. . An unusual and special feature of this channel is a fused functional kinase domain at its C-terminus.
Cancer is one of the major causes of mortality worldwide, and accounted for 8.2 million deaths 2012. Cancer hallmarks include rapid and uncontrolled cell proliferation at early stages, followed by invasion of surrounding tissues and metastasis during advanced stages of the disease. Dyshomeostasis of cations is one of the features accompanying carcinogenesis. In particular, an increase in the Ca 2+ /Mg 2+ ratio is associated with higher risk of postmenopausal breast cancer [1] , and high grade prostate cancer [2] . In prostate cancer cells, an increase in the Ca 2+ /Mg 2+ ratio correlates with increased Ca 2+ influx through the transient receptor potential melastatin type 7 (TRPM7) channel, and leads to enhanced proliferation [3] .
TRPM7 is a non-selective, cationic channel permeable to both Ca 2+ and Mg 2+ and is important for regulation of Mg 2+ homeostasis in mammals [4] . An unusual and special feature of this channel is a fused functional kinase domain at its C-terminus.
The role of this kinase in TRPM7 and its relation to cancer development are gradually being elucidated.
We herein summarize the two main functions of TRPM7 in both normal cell physiology and in cancer.
The dual function TRPM7 chanzyme TRPM7 and its homolog TRPM6 are two unique, bifunctional proteins featuring a channel and an enzyme in the same polypeptide sequence and are termed "chanzymes" [5] . In 2001, TRPM7 was shown to be comprised of the TRP-PLIK (TRP phospholipase C interacting kinase) channel [6] and LTRPC7 (long TRP channel type 7) [7] in CHO-K1 and HEK-293 cell lines. The TRPM7 alpha-subunit is a ∼220 kD polypeptide that is expressed in most human tissues [7] . The TRPM7 doi:10.1684/mrh. 2014.0367 channel is permeable to divalent cations, mainly Ca 2+ and Mg 2+ [7, 8] , but it can also conduct other metal ions such as zinc (Zn 2+ ), nickel (Ni 2+ ), and cadmium (Cd 2+ ) [9] . Mg 2+ has a specific binding site on an external face of the TRPM7 pore region and may compete with monovalent cations [10] . Consequently, monovalent cations cannot pass through the TRPM7 pore in the presence of external Mg 2+ . TRPM7 is responsible for the magnesium inhibited cation (MIC) and for the magnesium nucleotide modulated (MagNum) currents. The TRPM7-mediated current is blocked by the binding at its C-terminus of Mg 2+ , or Mg linked with nucleotides (MgNTP). The binding site for free Mg 2+ is found near to the channel pore, whereas the MgNTP binding site is localised to the kinase domain. In mutants lacking the kinase domain ( -kinase), TRPM7 becomes more sensitive to free Mg 2+ and loses its sensitivity to MgNTP [11] . Recent studies suggest however, that TRPM7 possesses not one, but two different binding sites for free Mg 2+ , one low affinity, and the other high affinity [12, 13] . Importantly, TRPM7 has been shown to be a key regulator of Mg 2+ homeostasis in humans [4] .
While permeability of the channel to cations has been well characterized, little is known about substrates for the TRPM7 Ser/Thr kinase, and only four endogenous substrates have so far been identified. TRPM7 phosphorylates the myosin IIA heavy chain, which leads to filament stability and specific cell morphology [14, 15] , the annexin A1 protein regulating its binding properties with membranes and the S100A11 protein [16, 17] , the eukaryotic elongation factor 2 (eEF2) via the eEF2-kinase [18] , and the c2-domain of phospholipase C␥2 [19] . Massive autophosphorylation of the catalytic domain of TRPM7 may facilitate kinase-substrate interaction and phosphorylation [20] . In addition, the TRPM7 kinase, like other atypical alpha-kinases, responds to local changes in Mg 2+ concentration [21, 22] , and phosphorylation of eEF2 and phospholipase C (PLC) by TRPM7 has been shown to be regulated by Mg 2+ availability [18, 19] . Finally, the data that involve the effects of the kinase domain on channel function remain controversial. In some reports, complete deletion of the kinase domain was shown to affect channel function [11, 21, 48] , while others showed that point mutation in the catalytic site did not change channel current amplitude or sensitivity to Mg 2+ [21, 23] , suggesting that the kinase domain is not required for channel activity, but may play a structural role in channel assembly or subcellular localization [23] .
TRPM7 in cell physiology
TRPM7 is involved in a number of vital cellular processes in mammalian cells, such as cell proliferation, migration, adhesion, differentiation, apoptosis and necroptosis. It is crucial for embryonic development at the molecular level, as regards both its channel function and kinase activity (figure 1).
Cell proliferation
A role for TRPM7 in proliferation has been proposed based on experiments involving modifications of gene expression. Cells deficient for TRPM7 (TRPM7 -/-) lose their ability to proliferate, and quickly die after a few days in culture [6, 8] . This effect has been attributed to Mg [8] . In support of this concept, proliferation of DT40 cells is regulated by Mg 2+ influx through TRPM7 and activation of the PI3K pathway [24] [25] [26] . Both hypotheses are supported by the findings that growth and proliferation of lymphocytes deficient in TRPM7 may be restored by heterologous expression of Mg 2+ transporters including SLC41A1, SLC41A2, MagT1, or MgtE [27] [28] [29] . Moreover, the TRPM7 current varies during the cell cycle in RBL-2H3 cells, with lower amplitude during G 0 , S, G 2 and M phases, whereas extracellular Mg 2+ is required particularly for G 1 phase entry when the TRPM7 current is increased [30] .
TRPM7 is also involved in Ca 2+ -dependent proliferation of several cell types including cardiac fibroblasts [31] and osteoclasts [32] . In the latter case, TRPM7-dependent cell proliferation was also sensitive to external Mg 2+ availability. Moreover, the MagNum current and the subsequent Ca 2+ influx were increased in the G1 cell cycle phase of rat mast cells [30] . Importantly, it should be mentioned that TRPM7 regulates cell proliferation mainly by the channel activity mediating influxes of both Ca 2+ and Mg 2+ . binding site localized near to the pore channel, and an MgNTP binding site localized to the kinase domain. TRPM7 is involved in many cellular processes through both its channel and kinase functions. The channel is implicated in cell proliferation, migration, adhesion, apoptosis and necroptosis through its calcium influx, while its magnesium influx regulates proliferation and apoptosis. Concerning the kinase domain, four substrates have been identified to be phosphorylated by its Ser/Thr activity, including myosin IIA and annexin I leading to cell adhesion and migration/invasion, respectively; and eEF2 and PLC with Mg 2+ -sensitive phosphorylation. Myosin IIA: myosin IIA heavy chain; PLC: phospholipase C; eEF2: the eukaryotic elongation factor 2.
Cell migration
The first evidence of the role of TRPM7 in control of cell migration was obtained from the experiments on the regulation of cell adhesion by TRPM7 through m-calpain activation by local calcium influx into peripheral adhesion complexes [33] . Similarly, TRPM7 has been found to co-localize with the KCa3.1 channel in the uropod of migrating T-cells leading to enhanced Ca 2+ influx in this cell compartment [34] . In fibroblasts, TRPM7 plays an essential role in the control of cytoskeleton assembly, and in polarized cell movements via Mg 2+ influx, independent of the kinase activity [35] .
While the above studies suggest that the channel portion of TRPM7 is responsible for the effects on cell adhesion and migration, other research demonstrates that TRPM7 involvement in cell migration and invasion can be mediated by both channel function and kinase activities. Indeed, regulation of cell adhesion by TRPM7 is the combined effect of Ca 2+ -and kinasedependent pathways on actomyosin contractility and podosome formation through phosphorylation of myosin IIA heavy chain [14] . In addition, TRPM7 is involved in bradykinin-induced cell migration and invasion through Mg 2+ influx and annexin 1 activation in human and rat vascular smooth muscle cells [36] .
Apoptosis and necroptosis
TRPM7 has been shown to be involved in apoptosis induced by Fas receptor activation [37] . Caspase-8 is able to cleave TRPM7 leading to the liberation of the kinase domain into the cytosol followed by the enhancement of cationic currents [37] . Reduction of TRPM7 expression in hepatic stellate cells increases TRAIL-induced apoptosis [38] . Recently, it has been reported that TRPM7 regulates neuronal apoptosis in a model of oxygenglucose deprivation/reoxygenation [39] . In this model, TRPM7 kinase interacts with annexin 1/myosin IIA complex leading to nuclear translocation of annexin 1 carried by myosin IIA prior to apoptosis signaling. TRPM7 is also involved in apoptosis by way of an Mg 2+ -dependent mechanism, as Chen et al. showed that TRPM7 regulates 3T3 fibroblast apoptosis through Mg 2+ influx and ROS production in response to cell stress [40] .
Finally, TRPM7 is also involved in so-called necroptosis, a programmed necrosis induced by external stimuli when apoptosis is inhibited. TRPM7 participates in Ca 2+ influx secondarily to TNF activation and MLKL (mixed lineage kinase domain-like protein) signaling, leading to necroptosis [41] .
Embryonic development and cell differentiation
Experiments with TRPM7 knock-out mice (TRPM7 -/-) have demonstrated an arrest of development after day 7.5, indicating that TRPM7 is essential for embryonic development [4, 42, 43] . TRPM7 is involved in the development of organs including thymus [42] , bone [44, 45] , exocrine pancreas [46] , fat tissue [47] , and myocardium [48] . Moreover, TRPM7 expression correlates with hepatocyte differentiation [49, 50] . Indeed, TRPM7 currents are lower in terminally differentiated hepatocytes as compared to proliferating cells and hepatoma cell lines. Furthermore, TRPM7 was found to be important for the gastrulation phase of embryonic development, the effect mediated by control of Mg 2+ homeostasis, GTPase Rac activation, and polarized movements in embryonic cells [51] .
To summarize, TRPM7 is involved in a wide range of cell processes by virtue of its dual function ( figure 1) . TRPM7 is ubiquitously expressed in human tissues unlike TRPM6, whose expression is confined to epithelial tissues. Moreover, TRPM7 is overexpressed in developing organs and this channel is crucial for embryonic development as it regulates cell proliferation and migration.
Clinical significance of TRPM7 expression in cancer TRPM7 channels are expressed in various cancer cell lines. However, studies characterizing the channel in human cancer tissues are limited (table 1) . Immunohistochemistry experiments reveal augmented expression of TRPM7 in human pulmonary adenocarcinoma [52] , and a higher expression in human pancreatic and prostate adenocarcinomas when compared to normal tissues [46, 53] .
A few studies investigated correlations between TRPM7 expression levels and clinical parameters and they highlighted the major clinical relevance of TRPM7 expression to pancreatic, ovarian, and breast cancer development. Indeed, in pancreatic ductal adenocarcinoma, TRPM7 staining is stronger in high grade tumors, and importantly, TRPM7 expression is inversely correlated to patient survival [54] . TRPM7 is also highly expressed in ovarian carcinoma where it is significantly associated with decreased disease-free survival and overall survival [55] , suggesting that TRPM7 overexpression may be a potential biomarker of poor prognosis in patients with pancreatic and ovarian cancers.
In breast cancer, TRPM7 expression displays a distinct pattern with respect to invasiveness and estrogen receptor (ER) status. In ER + ductal adenocarcinoma, TRPM7 expression is higher in non-invasive cells and it correlates to a high mitotic index, large tumor size, and tumor grade. These observations are supported by in vitro studies showing a decrease in MCF-7 cell proliferation by specific TRPM7-targeted siRNA, suggesting that TRPM7 can be a proliferative marker of poorly differentiated hormone-dependent breast cancers [56, 57] . Recently, multivariate analysis confirmed that TRPM7 mRNA expression is an independent prognostic marker for both disease recurrence and development of metastases at distant sites in breast cancer [58] . Datasets from the Oncomine cancer microarray database were also analyzed and revealed higher TRPM7 mRNA levels in metastatic breast cancers as compared to primary breast cancers [59] . Furthermore, in ER -ductal adenocarcinoma, TRPM7 expression is higher in invasive cells from primary tumor sites and matchedinvaded lymph nodes than in non-invasive cells [60] . TRPM7-knockdown impairs migratory and Meng et al. [59] Guilbert et al. [60] invasive properties of invasive triple-negative MDA-MB-231 and MDA-MB-435s breast cancer cells in vitro [58] [59] [60] , and it interferes with the metastatic potential of MDA-MB-231 cells in vivo [58] . Altogether, these results demonstrate that TRPM7 is a novel, strong independent marker for breast cancer progression and metastatic activity, particularly in the case of triple-negative breast cancers.
Finally, TRPM7 expression is increased in infiltrating ductal carcinoma with microcalcification when compared to age-matched controls without calcification or cancer [61] . It has been very recently shown that calcium influx through TRPM7 is a partial mediator of EGFinduced epithelial-mesenchymal transition (EMT) involving vimentin expression and STAT3 phosphorylation [62] , which confirms the role of TRPM7 in breast cancer progression.
TRPM7 regulates cancer cell responses by both ion channel function and kinase activity
For consideration of TRPM7 as a potential diagnostic and/or prognostic biomarker in cancers, we describe in more details the role of the chanzyme in cancer cell proliferation, migration and apoptosis.
Cell proliferation
TRPM7 MIC currents were first characterized in cancers using rat basophilic leukemia and retinoblastoma cells by Kozak et al. and Hanano et al., respectively [63, 64] . Pharmacological TRP channel blockers and siRNAs directed against TRPM7 decrease the MIC current Ca 2+ entry, as well as the proliferation of retinoblastoma cells that accumulate in turn in the G1/S phases of the cell cycle [63] . In support of this concept, it has been demonstrated that Ca 2+ entry through TRPM7 is involved in cell proliferation of the FaDu and SCC25 cancer cell lines derived from hypopharynx and thyroid, respectively [65] . Moreover, recent data obtained on the FaDu cellular model show that midazolam arrests the cells in the G0/G1 phases of the cell cycle, and that the action of midazolam is mediated by downregulation of TRPM7 expression rather than through activation of the benzodiazepine receptor [66] . Altogether, these results suggest that TRPM7 affects retinoblastoma and hypopharyngeal cancer cells through Ca 2+ entry into the cells [63, 65] . The same results were obtained in ER+ breast and prostate cancers, since TRPM7 mediates MCF-7 and DU145 cell proliferation in a Ca 2+ -dependent manner [3, 57] . On the other hand, two other studies on digestive system cancers demonstrated the role of TRPM7 in cell proliferation through Mg 2+ influx.
Indeed, in AGS human adenocarcinoma cells, TRPM7 and Mg 2+ are critical for survival and proliferation since growth defects in TRPM7-deficient cells can be rescued by supplemental Mg 2+ [67] . The same experiments were performed in PANC-1 and BxPC-3 pancreatic cancer cells showing the involvement of TRPM7 Mg 2+ influx in cell cycle progression via the Mg 2+ -sensitive Socs3a pathway [46] .
The regulation of TRPM7 channel activity and involvement in cancer cell proliferation was also investigated in WIF-B rat hepatoma cells. The results revealed that TRPM7 current was inhibited by cytosolic Ca 2+ in a CaMKII-dependent manner in these cells [50] , and by chloride and iodide through ATP-binding sites in the kinase domain and change of protein conformation leading to channel inactivation in MCF-7 breast cancer cells [68] . Moreover, TRPM7 calcium influx was shown to be activated by the serum Ca 2+ /Mg 2+ ratio and by cholesterol, and to be involved in cell proliferation through the Akt and Erk pathways [53] .
Cell migration
Several studies have demonstrated the role of TRPM7 in cell migration and invasion and have revealed that the molecular mechanisms involved depend on the cancer type. TRPM7 channel activity plays a pivotal role in lung cancer cell migration, since RNA interference and pharmacological approaches reversed basal migration and EGF-induced migration of A549 cells [52] . Furthermore, TRPM7-mediated calcium influx is involved in nasopharyngeal carcinoma cells [69] and in cholesterol-induced migration of prostate cancer cells [53] , whereas BxPC-3 pancreatic cancer cell migration is regulated by TRPM7-mediated magnesium influx [54] . Indeed, external supplementation of Mg 2+ following TRPM7 silencing fully restored BxPC-3 cell migration, indicating that TRPM7 is involved via an Mg 2+ -dependent mechanism.
In MDA-MB-435s triple-negative metastatic breast cancer cells, TRPM7 is involved in both migration and invasion processes by activating Src and MAPKinase, but not Akt pathways [59] . Another study performed in MDA-MB-231 demonstrates that TRPM7 regulates myosin II-based cellular tension, thereby modifying focal adhesion number, cell-cell adhesion and polarized cell movement, suggesting that TRPM7 is part of a mechanosensory complex adopted by cancer cells to drive metastasis formation [58] . The molecular mechanism was then further investigated and it has been revealed that TRPM7 is involved in MDA-MD-231 cell migration via its kinase domain and phosphorylation of myosin IIA, independently of calcium and magnesium influx [60] . In the same manner, TRPM7 regulates actomyosin contractility and invadosome formation independently of calcium influx in mouse N1E-115 neuroblastoma cells [70] .
Apoptosis and senescence
In addition to their established Mg 2+ sensitivity, TRPM7 channels are inhibited by cytosolic Ca 2+ (IC 50 = 125 ± 35 nM) in a CaMKII-dependent manner and might thereby support survival of proliferating and polarized rat hepatoma WIF-B cells [50] . Moreover, quercetin, a bioflavonoid with anti-cancer properties, inhibits TRPM7 currents and increases apoptosis in human gastric adenocarcinoma AGS cells [71] suggesting that TRPM7 is involved in apoptosis resistance. In BxPC-3 and Panc-1 pancreatic cancer cells, siRNA-mediated silencing of TRPM7 does not induce apoptotic cell death, but leads to replicative senescence, demonstrating that TRPM7 is required for preventing senescence [72] .
Conclusion and perspectives
The TRPM7 chanzyme is a dual function protein that displays different molecular mechanisms with respect to regulating specific cellular responses and cancer types. In summary, as a kinase, TRPM7 has been linked to cell migration and invasion through control of actomyosin contractility in ER -breast cancer and neuroblastoma, whereas channel permeability appears to be responsible for regulating cell proliferation and/or migration through Mg 2+ influx in pancreatic and gastric cancers, and through Ca 2+ influx in other cancers such as retinoblastoma, hypo-and naso-pharyngeal, prostate and ER + breast cancers ( figure 2) . In other words, cell proliferation is likely to be associated with TRPM7 channel activity, whereas cell migration and invasion seem to be linked to both channel and/or kinase activa- Figure 2 . TRPM7 involvement in cancer development. As a kinase, TRPM7 has been linked to cell migration and invasion through the control of actomyosin contractility in ER -breast cancer and neuroblastoma, whereas the channel has been found to regulate cell proliferation and/or migration through Mg 2+ influx in pancreatic and gastric cancers, and through Ca 2+ influx in other cancers such as retinoblastoma, hypo-and naso-pharyngeal, prostate and ER + breast cancers. Moreover, TRPM7 calcium influx is a partial regulator of EGF-induced epithelialmesenchymal transition (EMT) in breast cancer. tion. It is not possible to completely dissociate the TRPM7 channel and kinase functions as activation of one part of the molecule may depend on the other part. There are examples showing how Ca 2+ and Mg 2+ influxes may regulate the kinase domain and subsequently cell proliferation and migration [21, 22] . Despite the very preliminary information available, we would hypothesize that TRPM7 involvement changes during cancer progression: in early-stage tumors TRPM7 is involved in regulation of cell proliferation and migration as well as epithelial-mesenchymal transition through Ca 2+ and Mg 2+ homeostasis control, while cell migration and invasion in advanced-stage and aggressive tumors require TRPM7 kinase activity and interaction with cytoskeletal proteins. These data point to TRPM7 as a new diagnostic and prognostic marker, in addition to known biomarkers. Future efforts should be directed towards a better understand of the molecular mechanisms underlying TRPM7 regulation of cancerogenesis. There is growing evidence that TRPM7 can interact with accessory partners in a multimeric complex through its kinase domain. Thus, the TRPM7 kinase domain could act as an intracellular "fishing rod" by binding and phosphorylating signaling proteins to induce intracellular cascades promoting cancer. In addition, as it has been recently demonstrated the kinase domain may be cleaved from the channel portion and migrate into the nucleus to modulate gene expression, thus acting as an independent signaling molecule [73] .
A common challenge in TRP channel studies is the lack of specific and efficient pharmacological tools [74] despite the development of some promising molecules, such as waixenicin A [75] and quercetin [71] . Future efforts by chemists, biologists, and clinicians are warranted to develop novel therapeutic modalities specifically targeting the kinase domain in aggressive cancers.
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